CSL Seqirus wins BARDA award for H5N8 pre-pandemic vaccine

CSL Seqirus was selected by BARDA to manufacture and clinically assess an H5N8 A/Astrakhan virus vaccine candidate, with a Phase 2 clinical study anticipated to begin in Q2 2023.

“CSL Seqirus announced that the Biomedical Advanced Research and Development Authority... selected CSL Seqirus to deliver an H5N8 A/Astrakhan virus vaccine candidate for assessment in a Phase 2 clinical study that is anticipated to begin in Q2 2023.”biospace.com

• 1 source
• biospace.comCSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine - BioSpaceNick Paul TaylorOct 6, 2022

Summarized from public sources; check the original articles before acting on it.